# US 2017/0283468 A1 · Peptides for diagnosis and treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283468 A1
- Document ID: US20170283468A1
- Status: Published application
- Kind: A1
- Application number: 15/497,851
- Filed: 2017-04-26
- Published: 2017-10-05
- Earliest claimed: 2013-10-18
- Assignees: National Taiwan University
- Applicants: National Taiwan University
- Inventors: CHIN-TARNG LIN; HAN-CHUNG WU
- Web page: https://patentgrep.com/patent/US20170283468A1

## CPC

- C07K 14/005: from viruses
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- G01N 33/575: for cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients.

## Claims

### Claim 1

A method of reducing the side effects of cancer chemotherapy by using peptides, comprising:
administering to a subject suffering from a cancer an effective amount of a chemotherapeutic drug and peptides,
wherein the peptides are at least two selected from the group consisting of amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:6.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cancer is liver cancer, pancreatic cancer or lung cancer.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the peptides are amino acid sequences of SEQ ID NO:2 and SEQ ID NO:6.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the peptides are amino acid sequences of SEQ ID NO:1 and SEQ ID NO:6.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the peptides are amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the chemotherapy drug is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, cyclophosphamide, dacarbazine, temozolomide, gemcitabine, capecitabine, cladribine, clofarabine, cytarabine, floxuridine, fludarabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, thioguanadine, daunorubicin, doxurubicin, epirubicin, idarubicin, topotecan, irinotecan, etoposide, eniposide, colchicine, vincristine, vinblastine, vinorelbine, paclitaxel, docetaxel, and a combination thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the administering step is simultaneous or alternative administration.

### Claim 8

A method of reducing the side effects of cancer chemotherapy by using peptide, comprising:
administering to a subject suffering from a cancer an effective amount of
a first set comprising a first chemotherapeutic drug and a first peptide, and
a second set comprising a second chemotherapeutic drug and a second peptide,
wherein each the first peptide and the second peptide is selected from the group consisting of amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:6,
wherein the second set is administered a period of time after the first set.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the cancer is liver cancer, pancreatic cancer or lung cancer.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the first peptide is amino acid sequence of SEQ ID NO:2 and the second peptide is amino acid sequences of SEQ ID NO:6.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the first peptide is amino acid sequence of SEQ ID NO:1 and the second peptide is amino acid sequences of SEQ ID NO:6.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the first peptide is amino acid sequence of SEQ ID NO:1 and the second peptide is amino acid sequences of SEQ ID NO:2.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the first chemotherapeutic drug is the same as or different from the second chemotherapeutic drug.

### Claim 14 (depends on 8)

The method according to claim 8, wherein the first peptide is the same as or different from the second peptide.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the chemotherapy drug is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, cyclophosphamide, dacarbazine, temozolomide, gemcitabine, capecitabine, cladribine, clofarabine, cytarabine, floxuridine, fludarabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, thioguanadine, daunorubicin, doxurubicin, epirubicin, idarubicin, topotecan, irinotecan, etoposide, eniposide, colchicine, vincristine, vinblastine, vinorelbine, paclitaxel, docetaxel, and a combination thereof.
